Jim Simons acquired 2.37M Neurocrine Biosciences shares worth $332M. That's 0.42% of their equity portfolio (29th largest holding). The investor owns 2.40% of the outstanding Neurocrine Biosciences stock. The first Neurocrine Biosciences trade was made in Q3 2015. Since then Jim Simons bought shares sixteen more times and sold shares on fifteen occasions. The stake costed the investor $264M, netting the investor a gain of 26% so far.